Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.

Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M

Diabetic medicine : a journal of the British Diabetic Association1 Jul 2009Cited by 81 (Europe PMC)

PMID19573122PMCIDPMC2776933DOI10.1111/j.1464-5491.2009.02752.xPepBankPUB-19573122

Summary

AimsTo assess treatment satisfaction and weight-related quality of life (QOL) in subjects with Type 2 diabetes treated with exenatide once weekly (QW) or twice daily (BID).MethodsIn this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52. Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52. Mean group changes from baseline to week 30 were estimated by ancova; changes from week 30 to week 52 were assessed by Student's t-test.ResultsStatistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group. Effect sizes for change in DTSQ-s total scores were 0.84 QW, 0.64 BID; for IWQOL-Lite: 0.96 QW, 0.82 BID. Treatment satisfaction and QOL improved significantly between weeks 30 and 52 for those switching from BID to QW. Occurrence of adverse events did not affect patients' improvements in treatment satisfaction and QOL.ConclusionsPatients treated with exenatide QW or BID experienced significant and clinically meaningful improvements in treatment satisfaction and QOL. Patients who switched from exenatide BID to exenatide QW administration reported further significant improvements.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, weekly exenatide reduced perceived hyperglycemia frequency more than twice-daily exenatide.
In plain wordsIn patients with diabetes, weekly exenatide reduced perceived high blood sugar frequency more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePerceived hyperglycemia frequency
Study
n = 295
Comparator
Exenatide twice daily
Outcome group
Glycemic control · Metabolic and weight
Studied dose
once weekly · 30 weeksAs given in this study (human).
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312205
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, weekly exenatide improved satisfaction with continuing treatment more than twice-daily exenatide.
In plain wordsIn patients with diabetes, weekly exenatide improved satisfaction with continued treatment more than twice-daily exenatide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSatisfaction with continuing treatment
Study
n = 295
Comparator
Exenatide twice daily
Outcome group
Quality of life · Whole body
Studied dose
once weekly · 30 weeksAs given in this study (human).
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312206
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, once-weekly exenatide improved treatment satisfaction from baseline to week 30.
In plain wordsIn patients with diabetes, weekly exenatide improved treatment satisfaction compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment satisfaction with weekly dosing
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
once weekly · 30 weeksAs given in this study (human).
Measurements
DTSQ-s effect size
0.84 effect size
once weekly
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
3 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes for change in DTSQ-s total scores were 0.84 QW, 0.64 BID; for IWQOL-Lite: 0.96 QW, 0.82 BID.
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312201
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, twice-daily exenatide improved treatment satisfaction from baseline to week 30.
In plain wordsIn patients with diabetes, twice-daily exenatide improved treatment satisfaction compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment satisfaction with twice-daily dosing
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
twice daily · 30 weeksAs given in this study (human).
Measurements
DTSQ-s effect size
0.64 effect size
twice daily
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
3 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes for change in DTSQ-s total scores were 0.84 QW, 0.64 BID; for IWQOL-Lite: 0.96 QW, 0.82 BID.
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312202
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, once-weekly exenatide improved weight-related quality of life from baseline to week 30.
In plain wordsIn patients with diabetes, weekly exenatide improved weight-related quality of life compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight-related quality of life with weekly dosing
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
once weekly · 30 weeksAs given in this study (human).
Measurements
IWQOL-Lite effect size
0.96 effect size
once weekly
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
3 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes for change in DTSQ-s total scores were 0.84 QW, 0.64 BID; for IWQOL-Lite: 0.96 QW, 0.82 BID.
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312203
06HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, twice-daily exenatide improved weight-related quality of life from baseline to week 30.
In plain wordsIn patients with diabetes, twice-daily exenatide improved weight-related quality of life compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight-related quality of life with twice-daily dosing
Study
n: not reported in source
Comparator
Baseline
Outcome group
Quality of life · Whole body
Studied dose
twice daily · 30 weeksAs given in this study (human).
Measurements
IWQOL-Lite effect size
0.82 effect size
twice daily
Source sentences
Summary
Statistically significant improvements from baseline to week 30 were observed in both treatment groups for DTSQ-s and IWQOL-Lite measures, with significantly greater reduction in perceived frequency of hyperglycaemia and greater satisfaction with continuing treatment in the QW group compared with the BID group.
3 context sentences(design, population, supporting numbers)
Summary · context
Effect sizes for change in DTSQ-s total scores were 0.84 QW, 0.64 BID; for IWQOL-Lite: 0.96 QW, 0.82 BID.
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312204
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, treatment satisfaction improved after switching from twice-daily to weekly exenatide.
In plain wordsIn patients with diabetes, satisfaction improved after switching to weekly exenatide compared with before the switch.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseTreatment satisfaction after dosing switch
Study
n: not reported in source
Comparator
Week 30
Outcome group
Quality of life · Whole body
Studied dose
once weekly after twice daily · weeks 30-52As given in this study (human).
Source sentences
Summary
Treatment satisfaction and QOL improved significantly between weeks 30 and 52 for those switching from BID to QW.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312207
08HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, quality of life improved after switching from twice-daily to weekly exenatide.
In plain wordsIn patients with diabetes, quality of life improved after switching to weekly exenatide compared with before the switch.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseQuality of life after dosing switch
Study
n: not reported in source
Comparator
Week 30
Outcome group
Quality of life · Whole body
Studied dose
once weekly after twice daily · weeks 30-52As given in this study (human).
Source sentences
Summary
Treatment satisfaction and QOL improved significantly between weeks 30 and 52 for those switching from BID to QW.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
Show in the study text Report a problemFND-1957312208

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

09HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In exenatide-treated patients with type 2 diabetes, adverse event occurrence did not affect treatment satisfaction improvements.
In plain wordsIn patients with diabetes taking exenatide, adverse events did not affect improvements in treatment satisfaction.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse event influence on treatment satisfaction
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Source sentences
Summary
Occurrence of adverse events did not affect patients' improvements in treatment satisfaction and QOL.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-1957312209
10HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome
In exenatide-treated patients with type 2 diabetes, adverse event occurrence did not affect quality of life improvements.
In plain wordsIn patients with diabetes taking exenatide, adverse events did not affect improvements in quality of life.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse event influence on quality of life
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Source sentences
Summary
Occurrence of adverse events did not affect patients' improvements in treatment satisfaction and QOL.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 52-week randomized, multi-centre, open-label study, 295 subjects managed with diet and exercise and/or oral glucose-lowering medications received either exenatide QW or BID during weeks 1-30; thereafter, subjects receiving exenatide BID were switched to exenatide QW, with 258 total subjects receiving exenatide QW during weeks 30-52.
Summary · context
Diabetes Treatment Satisfaction Questionnaire-status (DTSQ-s) and Impact of Weight on Quality of Life-Lite (IWQOL-Lite) were assessed at baseline and weeks 30 and 52.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Show in the study text Report a problemFND-1957312210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.